Efficacy analysis of a phase III study of androgen deprivation therapy (ADT) +/- docetaxel (D) for men with biochemical relapse (BCR) after prostatectomy.-Reference-Cited by-同舟云学术

Efficacy analysis of a phase III study of androgen deprivation therapy (ADT) +/- docetaxel (D) for men with biochemical relapse (BCR) after prostatectomy.

Published:2015-05-20 Issue:15_suppl Volume:33 Page:5011-5011
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Morris Michael J.¹,Hilden Patrick¹,Gleave Martin Edwin²,Armstrong Andrew J.³,Carducci Michael Anthony⁴,Saad Fred⁵,Dayan Erica Simone¹,Filipenko Julie¹,Acosta Ilyse¹,Heller Glenn¹,Scher Howard I.¹

Affiliation:

1. Memorial Sloan Kettering Cancer Center, New York, NY

2. University of British Columbia, Vancouver, BC, Canada

3. Duke Cancer Institute, Duke University, Durham, NC

4. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD

5. University of Montreal, Montreal, QC, Canada

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2015.33.15_suppl.5011

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy;European Urology Open Science;2021-12

2. Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy;JAMA Oncology;2019-05-01

3. Time for an Integrated Global Strategy to Decrease Deaths from Prostate Cancer;European Urology Focus;2019-03

4. Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies;European Urology;2018-06

5. Drug development for noncastrate prostate cancer in a changed therapeutic landscape;Nature Reviews Clinical Oncology;2017-10-17